Table 4

Outcomes of the OAB economic model for the base-case scenario

Treatment

Continent at Week 12

Continent at Week 52

QALY gain

Total costs ()

ICER


Fesoterodine

50.6%

33.08%

0.01014

1,937

-


Tolterodine

40.6%

26.53%

0.00846

2,089

Cost-saving


Solifenacin

47.2%

30.85%

0.00957

1,960

Cost-saving


ICER = Incremental cost-effectiveness ratio

Arlandis-Guzman et al. BMC Urology 2011 11:9   doi:10.1186/1471-2490-11-9

Open Data